Talk:Inclacumab
Add topicLatest comment: 7 years ago by Spintendo in topic Edit request
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Inclacumab.
|
Edit request
[edit]
 | Part of an edit requested by an editor with a conflict of interest has been implemented. [See below] |
Dear editor On the https://en.wikipedia.org/wiki/Inclacumab page it states that "This drug was developed by Genentech/Roche". The development was however done by Genmab/Roche Some materials in which this is shown are included below:
Investor relations presentation Genmab June 2014, page 21 [1] Scientific Publication on inclacumab [2] Financial result update Q3 2013, page 9 of 29 [3] Patent Genmab of the antibody [4]
Thank you for your consideration Kind regards, Joostmelis (talk) 09:30, 18 March 2019 (UTC) Joostmelis
References
Reply -MAR-2019
[edit]
Edit request partially implemented
- To state that the drug was developed by Genmab only tells part of the story. The antibody is outlicensed by Roche, meaning its initial development took place with Roche in part, after which Roche became responsible for it as a whole, thus all further developments of the antibody with respect to the treatments of conditions occurs with whichever company outlicenses the antibody from Roche. Stating only one overall type of development as occuring would therefore be deficient. The article has been changed to reflect Roche's role as outlicensing agent for the antibody rather than as its developer.
Regards, Spintendo 12:12, 18 March 2019 (UTC)